• Je něco špatně v tomto záznamu ?

Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis

J. Szilasiova, P. Mikula, J. Rosenberger, M. Fedicova, P. Urban, L. Frigova, M. Vitkova, Z. Gdovinova, J. Hanes, E. Stevens

. 2022 ; 166 (3) : 304-311. [pub] 20210601

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22022914

BACKGROUND: Neurofilament light chain is a promising biomarker of disease activity and treatment response in relapsing-remitting multiple sclerosis (MS). Its role in progressive MS is less clear. AIM: The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept NEDA-3 (No Evident Disease Activity), and brain volumetry, in a cohort of patients with the progressive disease form (PMS). METHODS: Levels of pNfL (SIMOA technology) were examined in 52 PMS patients and analysed in relationship to NEDA-3 status and annual brain volume loss (BVL) during the last 12 months. The statistical model was developed using logistic regression analysis, including demographic, clinical and magnetic resonance imaging (MRI) data as independent variables. Dependent variables were NEDA-3 status and BVL. RESULTS: The mean age of the study participants (n=52, 50% females) was 45.85 (SD, 9.82) and the median disability score was 5.0 (IQR: 5.0-5.5). ROC analysis showed that pNfL predicts NEDA-3 (the sensitivity and specificity of the model were 77.8% and 87.6%, respectively, P<0.001) and abnormal BVL (the sensitivity and specificity were 96.6% and 68.2%, respectively, P<0.001). CONCLUSIONS: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA-3 status, including brain MRI-volumetry, in patients with the progressive form of MS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22022914
003      
CZ-PrNML
005      
20230118155259.0
007      
ta
008      
221007s2022 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2021.034 $2 doi
035    __
$a (PubMed)34092793
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Szilasiová, Jarmila $u Department of Neurology, Pavol Jozef Safarik University in Kosice, Slovak Republic $u Department of Neurology, L. Pasteur University Hospital, Kosice, Slovak Republic $7 xx0145956
245    10
$a Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis / $c J. Szilasiova, P. Mikula, J. Rosenberger, M. Fedicova, P. Urban, L. Frigova, M. Vitkova, Z. Gdovinova, J. Hanes, E. Stevens
520    9_
$a BACKGROUND: Neurofilament light chain is a promising biomarker of disease activity and treatment response in relapsing-remitting multiple sclerosis (MS). Its role in progressive MS is less clear. AIM: The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept NEDA-3 (No Evident Disease Activity), and brain volumetry, in a cohort of patients with the progressive disease form (PMS). METHODS: Levels of pNfL (SIMOA technology) were examined in 52 PMS patients and analysed in relationship to NEDA-3 status and annual brain volume loss (BVL) during the last 12 months. The statistical model was developed using logistic regression analysis, including demographic, clinical and magnetic resonance imaging (MRI) data as independent variables. Dependent variables were NEDA-3 status and BVL. RESULTS: The mean age of the study participants (n=52, 50% females) was 45.85 (SD, 9.82) and the median disability score was 5.0 (IQR: 5.0-5.5). ROC analysis showed that pNfL predicts NEDA-3 (the sensitivity and specificity of the model were 77.8% and 87.6%, respectively, P<0.001) and abnormal BVL (the sensitivity and specificity were 96.6% and 68.2%, respectively, P<0.001). CONCLUSIONS: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA-3 status, including brain MRI-volumetry, in patients with the progressive form of MS.
650    _2
$a atrofie $7 D001284
650    _2
$a biologické markery $7 D015415
650    _2
$a mozek $x diagnostické zobrazování $x patologie $7 D001921
650    12
$a nemoci centrálního nervového systému $7 D002493
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a intermediární filamenta $7 D007382
650    _2
$a magnetická rezonanční tomografie $x metody $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    12
$a roztroušená skleróza $x diagnostické zobrazování $7 D009103
650    12
$a relabující-remitující roztroušená skleróza $x diagnostické zobrazování $x farmakoterapie $x patologie $7 D020529
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mikula, Pavol $u Department of Social and Behavioral Medicine, Pavol Jozef Safarik University in Kosice, Slovak Republic $7 xx0280701
700    1_
$a Rosenberger, Jaroslav $u Department of Health Psychology and Methodology of Research, II. Internal Clinic, Pavol Jozef Safarik University in Kosice, Slovak Republic $u Olomouc University Social Health Institute, Palacky University Olomouc, Czech Republic $7 xx0107298
700    1_
$a Fedičová, Miriam $u Department of Neurology, L. Pasteur University Hospital, Kosice, Slovak Republic $7 xx0250434
700    1_
$a Urban, Peter $u Department of Medical and Clinical Biochemistry, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Slovak Republic $7 xx0136439
700    1_
$a Frigová, Lýdia $u Pro Magnet Kosice, Slovak Republic $7 xx0280692
700    1_
$a Vítková, Marianna $u Department of Neurology, Pavol Jozef Safarik University in Kosice, Slovak Republic $u Department of Neurology, L. Pasteur University Hospital, Kosice, Slovak Republic $7 xx0250435
700    1_
$a Gdovinová, Zuzana, $u Department of Neurology, Pavol Jozef Safarik University in Kosice, Slovak Republic $u Department of Neurology, L. Pasteur University Hospital, Kosice, Slovak Republic $d 1959- $7 xx0240053
700    1_
$a Hanes, Jozef $u Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovak Republic $u AXON Neuroscience R&D Services SE, Bratislava, Slovak Republic
700    1_
$a Stevens, Eva $u AXON Neuroscience R&D Services SE, Bratislava, Slovak Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 166, č. 3 (2022), s. 304-311
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34092793 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20221007 $b ABA008
991    __
$a 20230118155254 $b ABA008
999    __
$a ok $b bmc $g 1885620 $s 1174200
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 166 $c 3 $d 304-311 $e 20210601 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK138 $a Pubmed-20221007

Najít záznam

Citační ukazatele

Možnosti archivace